NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.
Pharma & Biotech
Drug approvals, clinical trials, and news from the pharmaceutical and biotech industry.
Merck Faces Keytruda Patent Cliff
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?
Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.
